NPPA computed the Retail Price of Olmesartan Medoxomil IP 20 mg + Amlodipine Besilate IP Eq. to Amlodipine 5 mg + Hydrochlorothiazide IP 12.5 mg for M/s Windlas Biotech Limited (Manufacturer) & M/s Alkem Wellness Limited (Marketer)

Mar 03, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Compliance

The National Pharmaceutical Pricing Authority (NPPA) on February 26, 2026, issued the Computation of Retail Price of Olmesartan Medoxomil IP 20 mg + Amlodipine Besilate IP Eq. to Amlodipine 5 mg + Hydrochlorothiazide IP 12.5 mg for M/s Windlas Biotech Limited (Manufacturer) & M/s Alkem Wellness Limited (Marketer).

The following has been stated namely: -

• The Retail Price has been computed based on the data from July 2025

• The Retail Price has been computed for Each Film Coated Tablet Containing Olmesartan Medoxomil IP 20 mg + Amlodipine Besilate IP Eq. to Amlodipine 5 mg + Hydrochlorothiazide IP 12.5 mg for M/s Windlas Biotech Limited (Manufacturer) & M/s Alkem Wellness Limited (Marketer)

• The Total MAT is 539,275,589

[Notification No. 19(5013)/2026/DP/NPPA/Div.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT